Biohaven Ltd. (BHVN) Debt Components
- 2026-06-30: Debt Instrument, Fair Value DisclosureUSD $259.48M.
- 2026-03-31: Debt Instrument, Fair Value DisclosureUSD $241.91M.
- 2025-12-31: Debt Instrument, Fair Value DisclosureUSD $238.90M.
Biohaven Ltd. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Debt Instrument, Fair Value Disclosure USD |
|---|---|
| 2026-06-30 | $259.48M |
| 2026-03-31 | $241.91M |
| 2025-12-31 | $238.90M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |